Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3415 - A multicenter phase II trial to evaluate the efficacy of mFOLFOX6+cetuximab as induction chemotherapy to achieve R0 surgical resection for advanced colorectal liver metastases (NEXTO trial)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy;  Surgical Oncology

Tumour Site

Colon and Rectal Cancer

Presenters

YUJIRO NISHIOKA

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

Y. NISHIOKA1, K. Hasegawa1, A. Saiura2, M. Oba1, J. Yamamoto3, Y. Nomura4, T. Takayama5, Y. Hashiguchi6, M. Shibasaki7, H. Sakamoto8, S. Yamagata9, N. Aoyanagi10, H. Kaneko11, H. Koyama12, S. Miyagawa13, Y. Mise2, E. Shinozaki14, S. Yoshida15, H. Nozawa16, N. Kokudo1

Author affiliations

  • 1 Hepatobiliary-pancreatic Surgery Division, Department Of Surgery, The University of Tokyo, Graduate School of Medicine, 113-8655 - Tokyo/JP
  • 2 Department Of Surgery, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 3 Department Of Surgery, National Deffence Medical College, 359-8513 - Tokorozawa/JP
  • 4 Department Of Surgery, Asahi General Hospital, 289-2511 - Chiba/JP
  • 5 Department Of Digestive Surgery, Nihon University School of Medicine, 173-8610 - Tokyo/JP
  • 6 Department Of Surgery, Teikyo University School of Medicine, 173-8605 - Tokyo/JP
  • 7 Department Of Surgery, JCHO Tokyo Yamate Medical Center, 169-0073 - Tokyo/JP
  • 8 Gastrointestinal Surgery, Saitama Cancer Center, 3620806 - Saitama/JP
  • 9 Department Of Surgery, JCHO Tokyo Shinjuku Medical Center, 162-8543 - Tokyo/JP
  • 10 Department Of Surgery, Kohnodai Hospital, National Center for Global-Health and Medicine, 272-8516 - Chiba/JP
  • 11 Department Of Surgery, Toho University Faculty of Medicine, 143-8541 - Tokyo/JP
  • 12 Department Of Surgery, JCHO Tokyo Takanawa Hospital, 108-8606 - Tokyo/JP
  • 13 First Department Of Surgery, Shinshu University, School of Medicine, 390-8621 - Matsumoto/JP
  • 14 Department Of Gastroenterology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 15 Department Of Gastroenterology, The University of Tokyo, Graduate School of Medicine, 113-8655 - Tokyo/JP
  • 16 Department Of Surgical oncology, Tokyo University Hospital, 113-8655 - Tokyo/JP
More

Resources

Abstract 3415

Background

Hepatic resection is known to be the standard treatment for patients with colorectal liver metastasis (CRLM). The recent advancement in chemotherapy has led to the extended surgical indication and better outcome in patients with advanced CRLM. This phase II trial was designed to prospectively evaluate the validity of induction chemotherapy using mFOLFOX with cetuximab for advanced CRLM, which has been reported to provide early tumor shrinkage in CRLM with KRAS wild type.

Methods

Patients having advanced CRLM (tumor number > =5 and/or technically unresectbale) with KRAS wild type were included to this study. The induction of mFOLFOX with cetuximab was followed by the evaluation of surgical indication every 4 cycles (2 months). If all the tumors were regarded as technically resectable, we performed surgical resection after the waiting period of 1 month and postoperative chemotherapy was added until 12 cycles in total. If they were unresctable, we continued the regimen within the upper limit of 12 cycles. The primary endpoint was R0 resection rate. The secondary endpoints included recurrence free survival (RFS), progression free survival (PFS), and overall survival (OS).

Results

Between May 2012 and May 2015, total 50 patients were enrolled to this trial in 14 centers. The induction was not done in 2 patients, who were excluded. The median age of the 48 patients was 62.5 (range: 45 to 79) including 36 men and 12 women. The median tumor number detected by CT before the induction was 12 (1 to 57). R0 and R1 resections were performed in 26 and 5 patients, respectively (R0 resection rate: 54.2%), and there was no mortality. Under the median follow-up of 2.5 years, the 3-year RFS was 14.4%, 3-year PFS was 8.2%, 3-year OS was 60.0%, and median survival time was 3.4year.

Conclusions

For advanced CRLM with KRAS wild type, mFOLFOX with cetuximab induction therapy provided the sufficient R0 resection rate and favorable outcome.

Clinical trial identification

UMIN Clinical Trials Registry; C000007923.

Legal entity responsible for the study

The Institutional Review Board of each participating institutions.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.